drugset

drugset / Trial / NCT06907251

Dapagliflozin for Long COVID Syndrome

NCT06907251 ↗

Phase 3 Not yet recruiting 192 enrolled Ottawa Heart Institute Research Corporation

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.

Timeline

Start: 2026-09-01
Primary completion: 2028-06-30
Completion: 2029-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	10 mg	Oral

Indications